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Reply to Fekkar et al.
From the Authors:
We thank Fekkar and colleagues for their thoughtful comments on
our case series of patients with coronavirus disease (COVID-
19)–associated pulmonary aspergillosis (CAPA) (1). The main
points that are raised include the distinction between Aspergillus
colonization and invasive infection and the subsequent
classification. The presented cases are all classified as possible or
probable CAPA, and none are histologically proven invasive
aspergillosis, implying colonization without infection is a
possibility.
First, we acknowledge the association between chronic
obstructive pulmonary disease and Aspergillus spp. colonization.
In our letter, two patients with chronic obstructive pulmonary
disease are presented; here, we cannot rule out prior colonization.
In addition, one of these patients received systemic corticosteroids
for 2 days before admission, and one other patient was on a weaning
scheme of oral corticosteroids preadmission for rheumatoid arthritis.
A fourth patient with underlying bronchial asthma was treated with
inhalation fluticasone for 1 month before admission. The use of
corticosteroids is a known risk factor for colonization and invasive
aspergillosis. However, the patients described in our series received a
low daily dosage or a short duration of corticosteroids.
Cohort studies in patients with influenza-associated pulmonary
aspergillosis (IAPA) in the ICU demonstrated that any indication of
Aspergillus through positive culture or galactomannan (GM)
detection is highly indicative of invasive aspergillosis (2). In this
specific setting, a single positive test, such as serum GM or BAL
GM, is considered sufficient to classify probable IAPA according to
an expert panel. Both influenza and treatment with corticosteroids
are considered risk factors for IAPA (3).
The direct microscopy findings of respiratory samples for
fungal hyphae have no additional diagnostic value to the
presented workup according to the latest criteria for IAPA (3).
Nor can the criteria presented by Schauwvlieghe and colleagues
rule out invasive pulmonary aspergillosis in the presented
cases (2).
Furthermore, we would like to state that the start of antifungal
therapy was always in multidisciplinary consultation on the basis
of clinical deterioration and after reasonably excluding other
causes. Indeed, a sole positive culture for Aspergillus might simply
indicate colonization. However, rapid clinical deterioration with
positive mycological evidence could not be ignored after the first
cases of presumed CAPA with high mortality. We emphasize that
starting antifungal therapy should always be considered in the
context of the clinical status and in consultation with the
attending ICU physicians. The overuse of antifungal treatment
should be limited, because of adverse events such as liver and
renal damage as well as the financial costs and the selection of
resistant isolates.
The pathogenesis of COVID-19 is different from that of
influenza, both regarding the tropism of the virus as well as the effect
of the virus on (fungal) host defenses (4). As a consequence, the risk
of invasive aspergillosis in patients with COVID-19 infection may
be lower than in patients with influenza. Reports of presumed
CAPA cases that survive without antifungal therapy, such as those
presented by Fekkar and Alanio, are very informative and suggest
that in patients with COVID-19, Aspergillus colonization is more
common compared with in patients with influenza (5). In patients
with COVID-19, additional factors, such as corticosteroid therapy,
might contribute to an increased risk for developing invasive
aspergillosis.
We agree with Fekkar and colleagues that a more
stringent classification may be required for CAPA cases
compared with existing classifications. Ultimate proof of
CAPA can only be obtained through showing invasive hyphal
growth in tissue samples. A recent case series included four
proven CAPA cases, all of which were BAL culture and
GM positive (6). However, all four cases were serum GM
negative, underscoring the need for a better understanding
of the pathophysiology of CAPA and the performance of
diagnostic tests. Facing this uncertainty, in critically ill
patients with COVID-19, the risk of further diagnostic
testing, including bronchoscopy and/or lung biopsy, should be
carefully weighed against delaying the initiation of antifungal
therapy.
In conclusion, one mycological argument on a respiratory
sample does not prove invasive aspergillosis. However, clinical
deterioration in critically ill patients with COVID-19 that is
not due to other causes, such as thromboembolic complications,
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inflammatory diseases, or secondary bacterial or viral infection,
may indicate aspergillosis. However, radiological presentation
can be atypical for invasive fungal disease in COVID-19
pneumonia, resembling influenza. The quantity of mycological
arguments or the variety of assays is not decisive, although the
quality of clinical specimens is conclusive for proving invasive
aspergillosis. n
Author disclosures are available with the text of this letter at
www.atsjournals.org.




Leiden University Medical Centre
Leiden, the Netherlands






Tom A. Rijpstra, M.D.
Huub N. A. Belderbos, M.D.
Peter van Wijngaarden, M.D.
Amphia Hospital
Breda, the Netherlands
Paul E. Verweij, M.D., Ph.D.
Radboud University Medical Centre
Nijmegen, the Netherlands
and
Center of Expertise in Mycology Radboudumc/CWZ
Nijmegen, the Netherlands
ORCID IDs: 0000-0002-9958-2842 (R.G.B.); 0000-0003-3391-9200 (A.L.E.v.A.);
0000-0002-8600-9860 (P.E.V.).
*Corresponding author (e-mail: robbertbentvelsen@gmail.com).
References
1. van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij
PE, Bentvelsen RG. COVID-19–associated pulmonary aspergillosis.
Am J Respir Crit Care Med 2020;202:132–135.
2. Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke
L, Van Tienen C, et al.; Dutch-Belgian Mycosis study group. Invasive
aspergillosis in patients admitted to the intensive care unit with
severe influenza: a retrospective cohort study. Lancet Respir Med
2018;6:782–792.
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TMEM16A Potentiation: Possible Drawbacks
To the Editor:
Dr. Danahay and colleagues present an interesting and timely study
of TMEM16A potentiation to increase the epithelial fluid secretion
and thereby enhance mucus clearance in cystic fibrosis (CF) (1).
They report that the novel compound ETX001 potentiates the
opening of TMEM16A channels and augments the magnitude of
the chloride current. In human cell and animal models, the
ETX001 effect was independent of CFTR function. The authors
conclude that the novel potentiator could also be suitable for
patients with CF without mutation in CFTR. However, when
previous investigations of TMEM16A are considered, this approach
may raise concerns with respect to safety.
TMEM16A, a protein encoded by the gene ANO1, is a calcium-
activated chloride channel robustly expressed not only in epithelial cells
but also in smooth muscle cells of airways, pulmonary and systemic
vessels, gastrointestinal smooth muscle cells, and the endothelial cells of
pulmonary arteries (2). The wide distribution of the channel indicates
diversity in its physiological functions, such as secreting chloride and
regulating vascular and gastrointestinal tone. In addition, in the
pacemaker cells of the gut, TMEM16A is important for peristalsis
generation. Under physiological conditions, TMEM16A is active at the
resting membrane potential, and the open probability is dependent on
the intracellular calcium concentration. The chloride current is
voltage-dependent and exhibits a greater current amplitude in a
depolarized state than at hyperpolarization.
In addition to its physiological function, TMEM16A can be
upregulated by, for example, ET-1 (endothelin-1), the transcription factor
HIF-1a, or IL, factors that have been found to be important players in the
pathology of pulmonary arterial hypertension (PAH). We have recently
reported that TMEM16A is strongly upregulated in remodeled
pulmonary arteries from patients with idiopathic PAH and that this
change causes the depolarization of pulmonary arterial smooth muscle
cells as well as a contraction of small pulmonary arteries (3). These
detrimental changes were reversed by TMEM16A silencing or its
pharmacological inhibition. We have shown that such inhibition reduced
the increased pulmonary vascular tone in both ex vivo and in vivo settings
and reversed pulmonary arterial remodeling, causing amelioration of
pulmonary hypertension and right ventricular strain in two independent
PAH animal models (3). TMEM16A overactivation was observed in
inflammatory lung diseases, in which it was strongly upregulated in
secretory cells and airway smooth muscle cells, significantly contributing
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